The remote control doesn’t trigger the self-destruction of the CAR T cells, but simply prompts them to disengage from their cancerous targets.

A new CAR T therapy design uses the approved drug venetoclax to temporarily disengage engineered immune cells from tumors.

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel ...

Coherus BioSciences shows underwhelming LOQTORZI sales and reliance on upcoming pipeline catalysts. Read why CHRS stock is ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells ...

Immunotherapy—which activates the body's own immune system to kill cancer cells—has not worked well against a rare and fatal liver cancer, but a new study finds an existing FDA-approved drug may allow ...

Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.

SLAMF6 is an immune cell receptor whose function was not clear. Does it activate or inhibit cells? The results so far have been contradictory. Now, scientists at the Institut de Recherches Cliniques ...

A quiet problem has followed cancer immunotherapy for years. The immune system can be taught to fight, then it fades.

“RedTail is a major leap forward in the delivery of genetic medicine via an engineered virus,” said Eric Poma, PhD, Chief Executive Officer of Calidi. “It is able to avoid immune clearance allowing ...

After nearly 40 years of research on how Listeria bacteria manipulate our cells and battle our immune system to cause ...